Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
Novo Nordisk shares rose Wednesday after third-quarter earnings exceeded expectations, driven by Wegovy pill sales that surpassed Wall Street estimates. While Eli Lilly maintains dominance in the broader GLP-1 market through the growth of tirzepatide, Novo Nordisk has established an early advantage in oral weight loss medications. This shift comes as Novo's injectable semaglutide franchise stalls, contrasting with the strong performance of its oral pipeline. The company has raised its financial outlook following these results.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Novo Nordisk quarterly earnings exceeded expectations.
- ✓ Sales for the Wegovy pill surpassed consensus estimates.
- ✓ Eli Lilly maintains a lead in the GLP-1 market as tirzepatide grows.
- ✓ Novo Nordisk's injectable semaglutide franchise has stalled.
What changed
Novo Nordisk reported third-quarter earnings and Wegovy pill sales that beat analyst forecasts.
Live updates
-
Novo Nordisk gains ground in oral GLP-1 market as Lilly leads overall sector
Novo Nordisk shares rose Wednesday after third-quarter earnings exceeded expectations, driven by Wegovy pill sales that surpassed Wall Street estimates. While Eli Lilly maintains dominance in the broader GLP-1 market through the growth of tirzepatide, Novo Nordisk has established an early advantage in oral weight loss medications. This shift comes as Novo's injectable semaglutide franchise stalls, contrasting with the strong performance of its oral pipeline. The company has raised its financial outlook following these results.
Why it matters
Eli Lilly recently hit a $1 trillion market capitalization and holds a lead in injectable drug performance. Previous trials showed Lilly's retatrutide outperformed Novo's Ozempic in weight loss and blood sugar reduction. The competition has now shifted toward oral delivery methods to expand patient access.
What is confirmed
- Novo Nordisk quarterly earnings exceeded expectations.
- Sales for the Wegovy pill surpassed consensus estimates.
- Eli Lilly maintains a lead in the GLP-1 market as tirzepatide grows.
- Novo Nordisk's injectable semaglutide franchise has stalled.
What to watch next
- Further quarterly revenue data for Eli Lilly's oral pipeline
- Updates on the commercial rollout of retatrutide
confidence 90%Sources used for this update (4)
- www.cnbc.com — Novo shares jump as Wegovy pill sales impress, drugmaker hikes outlook
- finance.yahoo.com — Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
- sterlingcharts.com — GLP-1 Market Share by Company: Lilly vs Novo (2026) | Sterling
- www.biocentury.com — BioCentury - Lilly extends GLP-1 lead — except in orals
-
Eli Lilly Surpasses Trillion-Dollar Mark as Retatrutide Beats Ozempic
Eli Lilly has reached a market capitalization of $1 trillion following a raised revenue guidance of $91-92B driven by strong sales of Mounjaro and Zepbound. Meanwhile, clinical trial results show Eli Lilly's experimental drug retatrutide outperformed Novo Nordisk's Ozempic in both weight loss and blood sugar reduction for patients with type 2 diabetes. Patients using retatrutide lost an average of 44 to 47 pounds over an 80-week period, compared to approximately 21 pounds for those taking Ozempic. This clinical performance strengthens Eli Lilly's market position as rival Novo Nordisk faces financial losses amid the ongoing drug competition.
Why it matters
The escalating race in the GLP-1 pharmaceutical market highlights a shifting competitive balance between the two major drugmakers. Eli Lilly is capitalizing on robust demand for its existing treatments while preparing advanced candidates for regulatory review. Novo Nordisk must contend with these market pressures as its established products face clinical benchmarks from newer multi-receptor therapies.
What is confirmed
- Eli Lilly reached a $1 trillion market cap after raising 2026 revenue guidance to $91-92B on Mounjaro and Zepbound sales.
- Retatrutide helped patients with type 2 diabetes lose an average of 44 to 47 pounds over 80 weeks, compared with about 21 pounds for Ozempic.
Still unconfirmed
- A regulatory application for Eli Lilly's retatrutide is expected in the first quarter of 2027.
What to watch next
- Submission of the regulatory application for retatrutide expected in the first quarter of 2027
- Official regulatory decisions regarding Eli Lilly's pending application for retatrutide
- Subsequent financial reporting from Novo Nordisk to measure the impact of competitor drug performance
confidence 100%Sources used for this update (5)
- www.cdc.gov — About Protecting Yourself from Legionella in Hot Tubs
- www.cdc.gov — Talk. Test. Treat. | SAW | CDC
- www.biospace.com — Lilly’s retatrutide trounces Novo’s Ozempic in diabetes ...
- finance.yahoo.com — LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head ...
- startupfortune.com — Eli Lilly tops $1 trillion as Novo Nordisk eats the losses of ...
-
Novo Nordisk and Eli Lilly in Obesity Pill Race
Eli Lilly's weight-loss pill Foundayo nears European approval, positioning it as a competitor to Novo Nordisk's Wegovy. Lilly's strategy includes patients switching to Foundayo for maintenance after using injectable medications. Novo Nordisk is presenting efficacy data for an oral version of Wegovy.
Why it matters
The obesity pill market is highly competitive, with Eli Lilly and Novo Nordisk as key players. The European approval of Foundayo would give Lilly a significant edge. Novo Nordisk is trying to maintain its position with new data and strategies.
What is confirmed
- Eli Lilly's Foundayo is nearing European approval as a weight-loss pill.
- Novo Nordisk is presenting efficacy data for an oral version of Wegovy.
- Eli Lilly is promoting a strategy where patients switch to Foundayo for maintenance after using injectable medications.
Still unconfirmed
- No specific rumors found.
What to watch next
- European approval decision for Foundayo
- Efficacy data presentation for Novo Nordisk's oral Wegovy
- Market share updates for Eli Lilly and Novo Nordisk
confidence 75%Sources used for this update (3)
- help.naver.com — Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide | ZeroHedge
- 247wallst.com — Eli Lilly Rises 4% While Foundayo Nears European Approval ...
- www.thepharmaletter.com — How Novo and Lilly took different paths in obesity
-
EU regulator backs Eli Lilly weight-loss pill Foundayo
Eli Lilly is expanding its GLP-1 market share as the EU drug regulator recommended its weight-loss pill Foundayo for approval. This move positions Foundayo as the second approved GLP-1 pill in the European Union. Meanwhile, Novo Nordisk is attempting to maintain its position by presenting efficacy data for an oral version of Wegovy at ECO. Lilly is also promoting a strategy where patients switch to Foundayo for maintenance after using injectable medications.
Why it matters
The GLP-1 market is shifting from high list prices to a high-volume, lower-net-price model. Novo Nordisk has seen its stock price fall over 25% since early 2026, reducing its valuation to 11.83 times forward earnings.
What is confirmed
- The EU drug regulator recommended Eli Lilly's weight-loss pill Foundayo for approval.
- Foundayo is set to be the second GLP-1 pill approved in the EU.
Still unconfirmed
- Eli Lilly is advocating for patients to switch to Foundayo during the maintenance phase after using injectables.
What to watch next
- Final EU approval decision for Foundayo
- Novo Nordisk Q3 financial results
- Clinical data comparisons between oral Wegovy and Foundayo
confidence 90%Sources used for this update (3)
- pharmaphorum.com — Novo, Lilly trade oral GLP-1 data readouts at ECO
- www.cnbc.com — Eli Lilly's weight-loss pill wins EU drug regulator's ... - CNBC
- finance.yahoo.com — How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
-
Novo Nordisk stock falls as Eli Lilly captures GLP-1 market growth
Novo Nordisk is defending its market position with higher-dose Wegovy and an oral pill version while Eli Lilly captures most of the current growth in GLP-1 medicines. The industry business model is shifting toward high volume at lower net prices rather than high list prices. Novo Nordisk faces significant financial pressure, with its stock price dropping over 25% since the start of 2026. This decline has lowered the company's valuation to 11.83 times forward earnings.
Why it matters
The GLP-1 market is projected to reach $190 billion by 2035. Both companies are currently developing amylin-targeting drugs to improve weight loss results. This competition follows a period where Eli Lilly dominated the first wave of treatments.
What is confirmed
- Eli Lilly is capturing most of the growth in the GLP-1 medicine market.
- The GLP-1 business model is shifting from high list prices to high volume at lower net prices.
Still unconfirmed
- Novo Nordisk is defending its market share using a Wegovy pill and higher-dose Wegovy.
What to watch next
- Clinical trial results for amylin-targeting combination therapies
- Market adoption rates for the oral Wegovy pill
- 2026 year-end revenue reports for Eli Lilly to verify the $87 billion projection
confidence 80%Sources used for this update (4)
- www.onedayadvisor.com — GLP-1 Investing Hub 2026: Eli Lilly, Novo Nordisk, Oral Pills ...
- www.insidermonkey.com — Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains Ground
- www.fool.com — Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?
- finance.yahoo.com — Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly ...
-
Novo and Lilly Bet on Amylin Drugs as GLP-1 Market Expands
Eli Lilly and Novo Nordisk are developing amylin-targeting drugs to complement or replace current GLP-1 obesity treatments, following early clinical trials that show significantly greater weight loss when combining amylin with existing medications. This strategic shift follows a period where Eli Lilly dominated the first wave of GLP-1 treatments and expects up to $87 billion in 2026 revenue. Meanwhile, the broader GLP-1 pharmaceutical market generated $79 billion in sales in 2025 and is projected to reach $190 billion by 2035, driven by surging global demand for weight loss therapies.
Why it matters
The intense commercial competition between Eli Lilly and Novo Nordisk highlights a rapidly evolving pharmaceutical sector where companies must continually innovate beyond standard GLP-1 medications. Early clinical data regarding amylin-targeting treatments point to the next phase of obesity care, as drugmakers seek competitive advantages through combination therapies. These pipeline developments come on the heels of massive market expansion, with total GLP-1 sales scaling rapidly toward long-term multi-billion-dollar projections.
What is confirmed
- Eli Lilly and Novo Nordisk are developing amylin-targeting drugs to complement or replace GLP-1 obesity medications.
- Early clinical trials show significantly greater weight loss when amylin-targeting drugs are combined with existing treatments.
- Eli Lilly dominated the first wave of GLP-1s and expects up to $87 billion in 2026 revenue.
- GLP-1 drugs generated $79 billion in sales in 2025.
- The GLP-1 market could reach $190 billion by 2035.
What to watch next
- Results from advanced clinical trials testing amylin and GLP-1 combination therapies
- Financial reports detailing whether Eli Lilly reaches its projected $87 billion in 2026 revenue
- Market share shifts between Novo Nordisk and Eli Lilly in the ongoing weight loss sector competition
confidence 100%Sources used for this update (5)
- www.cnbc.com — Biotechnology and Pharmaceuticals - CNBC
- rocketnews.com — Why Lilly and Novo are betting on amylin to power a new wave ...
- www.fool.com — Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's ...
- www.curzioresearch.com — Eli Lilly won the first round of the weight-loss boom. Who ...
- explodingtopics.com — GLP-1 Market Size and Sales Statistics (October 2026)
-
Novo Fights Back as Eli Lilly Gains Ground in GLP-1 Market
Eli Lilly continues to outpace Novo Nordisk in the weight loss sector with stronger patient growth and market share gains, while Novo pushes forward with its next commercial chapter. Novo reports strong performance for its oral Wegovy pill, which improves weight loss after patients switch from injections and has driven high prescription volumes since launching in January 2026. Simultaneously, both pharmaceutical giants are expanding their portfolios by developing new amylin-targeting drugs designed to complement or enhance existing GLP-1 offerings.
Why it matters
Ozempic and Wegovy previously transformed Novo Nordisk into one of the industry's biggest winners, but intensifying competition has caused the company to lose market share to Eli Lilly. Both companies are now diversifying their obesity and diabetes pipelines through mid-stage trials and combination regimens. The broader shift toward oral formulations is reshaping prescribing habits and manufacturing priorities across the pharmaceutical sector.
What is confirmed
- Eli Lilly continues to outpace Novo Nordisk in the weight loss market, supported by stronger patient growth and market share gains.
- Both Eli Lilly and Novo Nordisk are developing amylin-targeting drugs to complement or enhance existing GLP-1 obesity medications.
- Novo's oral Wegovy pill improves weight loss after people switch from injections.
- Eli Lilly's Foundayo was approved in April.
Still unconfirmed
- Novo Nordisk's oral Wegovy pill has surpassed three million prescriptions in just over five months.
- Eli Lilly CEO stated that 700,000 seniors have started GLP-1s after Medicare coverage.
- Eli Lilly CEO stated that one-third of new GLP-1 pill patients are taking Foundayo.
What to watch next
- Further clinical trial results for mid-stage amylin combination obesity regimens from Eli Lilly and Novo Nordisk.
- Adoption rates and prescription tracking for oral Wegovy versus Eli Lilly's Foundayo.
- Changes in insurance coverage and FDA decisions regarding next-generation obesity medications.
confidence 90%Sources used for this update (11)
- www.glp1authority.com — GLP-1 News & Updates — Daily Summaries | GLP1Authority
- www.cnbc.com — Companies - CNBC
- finance.yahoo.com — Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?
- finance.yahoo.com — Novo Looks Beyond GLP-1s as Competition Intensifies
- rocketnews.com — Why Lilly and Novo are betting on amylin to power a new wave ...
- glpobesitymindset.substack.com — GLP-1 by Novo Nordisk vs. Lilly
- peptidestaff.com — The Oral GLP-1 Race: How Novo Nordisk, Eli Lilly, and Pfizer ...
- peptidestaff.com — Oral GLP-1 Drugs Reshape the Obesity Market: How Novo Nordisk ...
- finance.yahoo.com — NVO vs. LLY: Novo’s CEO Says Confidence Is Gone. Lilly Is ...
- www.lqventures.com — GLP-1 Market: Next-Generation Obesity Competition | Oct 2026
- congress.net — Novo Nordisk's (NVO) Wegovy Pill Crushes Eli Lilly's (LLY ...
-
Novo Nordisk Reports Weight Loss Win as Eli Lilly Maintains Market Lead
Novo Nordisk achieved a Phase 3 trial victory with CagriSema, where adults with type 2 diabetes on a 1 mg/1 mg dose lost an estimated 12.4% of body weight over 60 weeks. Despite this, Eli Lilly continues to dominate the GLP-1 market with a market value of approximately $1.02 trillion, roughly six times that of Novo. Both companies are now diversifying their obesity and diabetes portfolios by developing new amylin drugs to supplement their existing GLP-1 offerings.
Why it matters
Novo Nordisk is attempting to diversify its strategy to counter patent expirations and modest growth targets. Eli Lilly currently holds a significant commercial advantage in market share and valuation. The competition is shifting toward oral medications and combined biological levers to treat obesity.
What is confirmed
- Eli Lilly and Novo Nordisk are developing new amylin drugs for obesity and diabetes treatment.
- Eli Lilly leads Novo Nordisk in the GLP-1 medicine market as of October 3, 2026.
- Eli Lilly reported Q2 revenue of $22.97 billion, a 48% increase.
- Eli Lilly has a market value of about $1.02 trillion, while Novo Nordisk is valued between $165 billion and $170 billion.
Still unconfirmed
- Eli Lilly plans to file retatrutide in Q1 2027.
What to watch next
- FDA decision on CagriSema and the Wegovy pill in Q4 2026
- Eli Lilly's filing of retatrutide in Q1 2027
confidence 85%Sources used for this update (9)
- pharmaboardroom.com — New Name, Same Problems: What ‘Novo’ Does Next
- rocketnews.com — Novo is betting on its next chapter as Eli Lilly gains more ...
- www.cnbc.com — Lilly, Novo bet on amylin obesity drugs after GLP-1s
- finance.yahoo.com — Novo Nordisk Just Beat Lilly in a Trial. Is the Comeback ...
- www.zacks.com — Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs ...
- www.biospace.com — Lilly builds commercial case for GLP-1 products over Novo ...
- www.fool.com — Eli Lilly's weight loss drug business
- www.onedayadvisor.com — Eli Lilly vs. Novo Nordisk — The GLP‑1 Market Showdown (2026 ...
- finance.yahoo.com — Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs ...
-
Novo Fails to Sway Investors During Capital Markets Day
Novo Nordisk presented a new growth strategy at its Capital Markets Day to diversify beyond its GLP-1 drugs amid patent expirations, but the presentation failed to convince investors. Market reaction was negative due to modest growth targets, causing stock prices to tumble. Meanwhile, rival Eli Lilly continues to gain ground in the competitive GLP-1 obesity and diabetes drug market. Analysts indicate that Lilly retains distinct competitive advantages that could help preserve its position at the top of the obesity drug market while Novo attempts its turnaround.
Why it matters
The pharmaceutical sector is experiencing intense competition in the high-demand obesity and diabetes treatment space. Novo Nordisk must navigate upcoming patent expirations while trying to convince financial markets of its long-term viability. Rival Eli Lilly holds strong advantages that complicate Novo's turnaround efforts.
What is confirmed
- Novo Nordisk presented a growth strategy at its Capital Markets Day.
- Investors reacted negatively to the strategy due to modest growth targets.
- Eli Lilly continues gaining ground in the competitive GLP-1 obesity and diabetes drug market.
Still unconfirmed
- Eli Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
What to watch next
- Market performance and closing stock prices following the Capital Markets Day presentation
- Further analyst assessments regarding Eli Lilly and Novo Nordisk market positions
confidence 95%Sources used for this update (5)
- www.cnbc.com — Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
- rocketnews.com — Novo is betting on its next chapter as Eli Lilly gains more ...
- biotech-insider.com — Novo Bets on a Next Chapter as Lilly Widens Its GLP-1 Lead
- longbridge.com — Novo is betting on its next chapter as Eli Lilly gains more ...
- allmind.ai — Novo is betting on its next chapter as Eli Lilly gains more ...
-
Novo Nordisk Retools Strategy as Eli Lilly Gains Ground
Novo Nordisk is betting on its next growth chapter as rival Eli Lilly gains more ground in the GLP-1 drug market. The company aims to launch more than five blockbuster drugs by 2030 and has established a pipeline sales target above $23 billion by 2035. However, the Ozempic maker faces persistent doubts from investors regarding these long-term goals. Consequently, Novo Nordisk stock has tumbled, falling more steeply than the broader market as leadership works to build market confidence during a capital markets day event.
Why it matters
The pharmaceutical giant is navigating intense competition in the lucrative GLP-1 treatment space where Eli Lilly continues to advance its position. These market pressures have directly impacted investor sentiment and share performance. Company leadership is attempting to reset market expectations through ambitious forward-looking product and revenue targets.
What is confirmed
- Novo Nordisk aims to launch more than five blockbuster drugs by 2030.
- Novo Nordisk stock tumbles amid persistent doubts about the company goals for 2030.
- Novo Nordisk set a pipeline sales target above $23 billion by 2035.
Still unconfirmed
- Eli Lilly is gaining more ground in GLP-1s, forcing Novo Nordisk to bet heavily on its next chapter.
What to watch next
- Progress on the more than five blockbuster drug launches targeted by 2030
- Investor reaction and stock performance following the capital markets day targets
- Execution of the pipeline sales target above $23 billion by 2035
confidence 90%Sources used for this update (8)
- reuters.com — Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says
- MarketWatch — Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030
- Endpoints News — Novo’s CEO knows the drugmaker needs to build confidence
- cnbc.com — Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
- Yahoo Finance — Novo Nordisk (NVO) Falls More Steeply Than Broader Market: What Investors Need to Know
- Seeking Alpha — Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine (NYSE:NVO)
- Yahoo Finance — Novo Nordisk (NVO) Sets Pipeline Sales Target Above $23 Billion By 2035
- simplywall.st — Novo Nordisk (NVO) Shares Dropped, So What Is Driving Attention Now?
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community